Neutral
Nektar Therapeutics has entered a new equity distribution agreement with Guggenheim Securities and H.C. Wainwright, allowing it to sell up to $150 mil...
Nektar Therapeutics has entered into an Equity Distribution Agreement for an at-the-market offering of up to $150 million in common stock through Gugg...
Neutral
Nektar Therapeutics reported a strong cash position exceeding $1 billion in Q1 2026 due to recent financing, despite a net loss of $44.9 million. The ...
Bearish
The Rosen Law Firm is reminding purchasers of Nektar Therapeutics (NASDAQ: NKTR) securities that the lead plaintiff deadline for a securities fraud la...
Nektar Therapeutics recently released positive 52-week maintenance data for its immune-modulating drug rezpegaldesleukin in atopic dermatitis and addi...